{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(12)"],"submitter":["Ali A"],"pubmed_abstract":["Despite progress in genomic characterization, no single prognostic marker that can be evaluated using an easy-to-perform and relatively inexpensive method is available for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs, which are stable, tumor- and tissue-specific molecules, are potentially ideal biomarkers, and we established an inter-laboratory validated method to investigate miR-21 as a prognostic biomarker in PDAC. The study samples of PDAC patients were recruited from a test cohort of Glasgow (n = 189) and three validation cohorts of Pisa (n = 69), Sydney (n = 249), and International Cancer Genome Consortium (ICGC) (n = 249). Tissue microarrays were used for miR-21 staining by chromogenic in situ hybridization (CISH). The patients were subdivided into no/low and high miR-21 staini"],"journal":["American journal of cancer research"],"pagination":["5668-5683"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9827095"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients."],"pmcid":["PMC9827095"],"pubmed_authors":["Morton J","Duthie F","Giovannetti E","Oien KA","Funel N","Gill AJ","Khan IN","Frampton AE","Evans TRJ","McKay CJ","Samra J","Ali A","Chang D","Jamieson NB","Sansom O","Biankin A"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients.","description":"Despite progress in genomic characterization, no single prognostic marker that can be evaluated using an easy-to-perform and relatively inexpensive method is available for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs, which are stable, tumor- and tissue-specific molecules, are potentially ideal biomarkers, and we established an inter-laboratory validated method to investigate miR-21 as a prognostic biomarker in PDAC. The study samples of PDAC patients were recruited from a test cohort of Glasgow (n = 189) and three validation cohorts of Pisa (n = 69), Sydney (n = 249), and International Cancer Genome Consortium (ICGC) (n = 249). Tissue microarrays were used for miR-21 staining by chromogenic in situ hybridization (CISH). The patients were subdivided into no/low and high miR-21 staini","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T07:22:33.322Z","creation":"2025-04-04T07:22:33.322Z"},"accession":"S-EPMC9827095","cross_references":{"pubmed":["36628279"]}}